Insights into dietary flavonoids as molecular templates for the design of anti-platelet drugs

Cardiovascular Research

Volumn 97, Issue 1, 2013, Pages 13-22

  Wright, Bernice ^a   Spencer, Jeremy P E ^a   Lovegrove, Julie A ^a   Gibbins, Jonathan M ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

Anti platelet drugs; Cardiovascular disease; Drug design; Flavonoid analogues; Flavonoids

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; APIGENIN; CATECHIN; CHRYSIN; CLOPIDOGREL; CYANIDIN 3 ARABINOSIDE; EPIGALLOCATECHIN GALLATE; FLAVAN 3 OL DERIVATIVE; FLAVANOL DERIVATIVE; FLAVONOID; FLAVONOL; GALLIC ACID; GENISTEIN; GLUCURONIDE; GRAPE SEED EXTRACT; ISOFLAVANONE; ISOFLAVONE; ISOFLAVONONE; KAEMPFEROL; PHOSPHOTRANSFERASE INHIBITOR; PLANT MEDICINAL PRODUCT; PRASUGREL; PYCNOGENOL; QUERCETIN; QUERCETIN 3 GLUCURONIDE; RESVERATROL; STILBENE; TICLOPIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CACAO; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DIET SUPPLEMENTATION; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; FOLLOW UP; HEART INFARCTION; HUMAN; HYDROGEN BOND; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SIGNAL TRANSDUCTION; SOYBEAN; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ANIMALS; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; COMPUTER-AIDED DESIGN; DIET; DRUG DESIGN; FLAVONOIDS; HUMANS; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; PLATELET AGGREGATION INHIBITORS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84871746740     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs304     Document Type: Review

References (126)

1. Hertog MGL, Hollman PCH, Katan MB. Content of potentially anticarcinogenic fla-vonoids of 28 vegetables and 9 fruits commonly consumed in the Netherlands. J Agric Food Chem 1992;40:2379-2383.
2. Justesen U, Knuthsen P, Leth T. Quantitative analysis of flavonols, flavones, and fla-vanones in fruits, vegetables and beverages by high-performance liquid chromatog-raphy with photo-diode array and mass spectrometric detection. J Chromatogr A 1998;799:101-110. (Pubitemid 28161212)
3. Hertog MGL, Feskens EJM, Hollman PCH, Katan MB, Kromhout D. Dietary antioxi-dant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. The Lancet 1993;342:1007-1011. (Pubitemid 23314801)
4. Crozier A, Lean MEJ, McDonald MS, Black C. Quantitative analysis of the flavonoid content of commercial tomatoes, onions, lettuce, and celery. J Agric Food Chem 1997; 45:590-595. (Pubitemid 127483672)
5. Macheix JJ, Fleuriet A, Billot J. Fruit Phenolics. Boca Raton, FL: CRC Press; 1990.
6. Hollman PCH, Arts ICW. Flavonols, flavones and flavanols-nature, occurrence and dietary burden. J Food Sci Agric 2000; 80:1081-1093. (Pubitemid 30319401)
7. Arts IC, van De Putte B, Hollman PC. Catechin contents of foods commonly consumed in the Netherlands. 2. Tea, wine, fruit juices, and chocolate milk. J Agric Food Chem 2000;48:1752-1757. (Pubitemid 30331520)
8. Mouly PP, Arzouyan CR, Gaydou EM, Estienne JM. Differentiation of citrus juices by factorial discriminant analysis using liquid chromatography of flavanone glycosides. J Agric Food Chem 1994;42:70-79.
9. Tomas-Barberan FA, Clifford MN. Dietary hydroxybenzoic acid derivatives and their possible role in health protection. J Sci Food Agric 2000;80:1024-1032. (Pubitemid 30319396)
10. Xu X, Wang HJ, Murphy PA, Cook L, Hendrich S. Daidzein is a more bioavailable soymilk isoflavone than is genistein in adult women. J Nutr 1994;124:825-832. (Pubitemid 24200587)
11. Xu X, Wang HJ, Murphy PA, Hendrich S. Neither background diet nor type of soy food affects short-term isoflavone bioavailability in women. J Nutr 2000;130:798-801. (Pubitemid 30173664)
12. Mazza G, Maniati E. Anthocyanins in Fruits, Vegetables, and Grains. Boca Raton, FL: CRC Press; 1993.
13. Keli SO, Hertog MGL, Feskens EJM, Kromhout D. Dietary flavonoids, antioxidant vitamins, and the incidence of stroke. Arch Int Med 1996;154:637-642. (Pubitemid 26095013)
14. McCullough ML, Peterson JJ, Patel R, Jacques PF, Shah R, Dwyer JT. Flavonoid intake and cardiovascular disease mortality in a prospective cohort of US adults. Am J Clin Nutr 2012;95:454-464.
15. Mursu J, Voutilainen S, Nurmi T, Tuomainen TP, Kurl S, Salonen JT. Flavonoid intake and risk of ischaemic stroke and CVD mortality in middle aged Finnish men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Br J Nutr 2008;100:890-895.
16. Sagara M, Kanda T, NJelekera M, Teramoto T, Armitage L, Birt N et al. Effects of dietary intake of soy protein and isoflavones on cardiovascular disease risk factors in high risk, middle-aged men in Scotland. J Am Coll Nutr 2004; 23:85-91. (Pubitemid 38202292)
17. de Kleijn MJ, van der Schouw YT, Wilson PW, Grobbee DE, Jacques PF. Dietary intake of phytoestrogens is associated with a favourable metabolic cardiovascular risk profile in postmenopausal US women: the Framingham study. J Nutr 2002; 132:276-282. (Pubitemid 34135607)
18. Knekt P, Jarvinen R, Reunanen A, Maatela J. Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ 1996;312:478-481. (Pubitemid 26061237)
19. Lagiou P, Samoli E, Lagiou A, Skalkidis Y, Katsouyanni K, Petridou E et al. Flavonoid classes and risk of peripheral arterial occlusive disease: a case-control study in Greece. Eur J Clin Nutr 2006;60:214-219.
20. Mennen LI, Sapinho D, de Bree A, Arnault N, Bertrais S, Galan P et al. Consumption of foods rich in flavonoids is related to a decreased cardiovascular risk in apparently healthy French women. J Nutr 2004;134:923-926. (Pubitemid 38456265)
21. Hertog MG, Sweetnam PM, Fehily AM, Elwood PC, Kromhout D. Antioxidant flavo-nols and ischemic heart disease in a Welsh population of men: the Caerphilly Study. Am J Clin Nutr 1997;65:1489-1494. (Pubitemid 27187762)
22. Van der Gaag MS, Van der Berg R, Van der Berg H, Schaafsma G, Hendriks HFJ. Moderate consumption of beer, red wine and spirits has counteracting effects on plasma antioxidants in middle-aged men. Eur J Clin Nutr 2000;54:586-591. (Pubitemid 30447327)
23. Hooper L, Kay C, Abdelhamid A, Kroon PA, Cohn JS, Rimm EB et al. Effects of chocolate, cocoa, and flavan-3-ols on cardiovascular health: a systematic review and meta-analysis of randomized trials. Am J Clin Nutr 2012;95:740-751.
24. Chiva-Blanch G, Urpi-Sarda M, Lorach R, Rotches-Ribalta M, Guillen M, Casas R et al. Differential effects of polyphenols and alcohol of red wine on the expression of adhesion molecules and inflammatory cytokines related to atherosclerosis: a randomized clinical trial. Am J Clin Nutr 2012;95:326-334.
25. Desch S, Kobler D, Schmidt J, Sonnabend M, Adams V, Sareban M et al. Low vs. higher-dose dark chocolate and blood pressure in cardiovascular high-risk patients. Am J Hypertens 2010;23:694-700.
26. Errichi BM, Belcaro G, Hosoi M, Cesarone MR, Dugall M, Feragalli B et al. Prevention of post thrombotic syndrome with Pycnogenolw in a twelve month study. Panminerva Med 2011;53 (Suppl. 1):21-27.
27. Dohadwala MM, Holbrook M, Hamburg NM, Shenouda SM, Chung WB, Titas M et al. Effects of cranberry juice consumption on vascular function in patients with coronary artery disease. Am J Clin Nutr 2011;93:934-940.
28. Weseler AR, Ruijters EJ, Drittij-Reijnders MJ, Reesink KD, Haenen GR, Bast A. Pleio-tropic benefit of monomeric and oligomeric flavonols on vascular health-a randomized controlled clinical pilot study. PLoSOne 2011;6:e28460.
29. Choquette S, Riesco E, Cormier E, Dion T, Aubertin-Leheudre M, Dionne IJ. Effects of soya isoflavones and exercise on body composition and clinical risk factors of cardiovascular diseases in overweight postmenopausal women: a 6-month double-blind controlled trial. Br J Nutr 2011;105:1199-1209.
30. Erlund I, Meririnne E, Alfthan G, Aro A. Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. J Nutr 2001;131:235-241. (Pubitemid 32115362)
31. Meyer H, Bolarinwa A, Wolfram G, Linseisen J. Bioavailability of apigenin from apiin-rich parsley in humans. Ann Nutr Metab 2006;50:167-172. (Pubitemid 43829804)
32. Hubbard GP, Wolffram S, Lovegrove JA, Gibbins JM. Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans. J Thromb Haemost 2004;2:2138-2145. (Pubitemid 40185773)
33. Holt RR, Lazarus SA, Sullards MC, Zhu QY, Schramm DD, Hammerstone JF et al. Procyanidin dimer B2 [epicatechin-(4beta-8)-epicatechin] in human plasma after the consumption of a flavonol-rich cocoa. Am J Clin Nutr 2002;76:798-804.
34. Graefe EU, Wittig J, Mueller S, Riethling AK, Uehleke B, Drewelow B et al. Pharma-cokinetics and Bioavailability of quercetin glycosides in humans. J Clin Pharmacol 2001;41:492-499. (Pubitemid 32381866)
35. Donovan JL, Bell JR, Kasim-Karakas S, German JB, Walzem RL, Hansen RJ et al. Cat-echin is present as metabolites in human plasma after consumption of red wine. J Nutr 1999;129:1662-1668. (Pubitemid 29406618)
36. Bell JRC, Donovan JL, Wong R, Waterhouse AL, German JB, Walzem RL et al. (+-)-catechin in human plasma after ingestion of a single serving of reconstituted red wine. Am J Clin Nutr 2000;71:103-108. (Pubitemid 30033591)
37. Rimm EB, Katan MB, Ascherio A, Stampfer MJ, Willett WC. Relation between intake of flavonoids and risk for coronary heart disease in male health professionals. Ann Int Med 1996;125:384-389. (Pubitemid 126449708)
38. Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 2007;81:362-370. (Pubitemid 46364477)
39. Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther 2001;69:14-23. (Pubitemid 32109323)
40. Lilja JJ, Juntti-Patinen L, Neuvonen PJ. Orange juice substantially reduces the bioavail-ability of the b-adrenergic-blocking agent celiprolol. Clin Pharmacol Ther 2004;75:184-190. (Pubitemid 38314867)
41. Bailey DG, Dresser GK, Kreeft JH, Munoz C, Freeman DJ, Bend Jr. Grapefruit-felodipine interaction: effect of unprocessed fruit and probable active ingredients. Clin Pharmacol Ther 2000;68:468-477.
42. Patrignani P. Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb Res 2003;110:281-286. (Pubitemid 37329826)
43. Barrett NE, Holbrook L, Jones S, Kaiser WJ, Moraes LA, Rana R et al. Future innovations in anti-platelet therapies. Br J Pharmacol 2008;154:918-939. (Pubitemid 351915054)
44. Vane Jr. Inhibition of prostaglandin synthesis as a mechanism of action for aspirinlike drugs. Nat New Biol 1971;231:232-235.
45. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003;110:255-258. (Pubitemid 37329821)
46. Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008;451:914-918.
47. 12 antagonism: promises and challenges. Arterioscler Thromb Vasc Biol 2008;28:S33-S38.
48. Angiolillo DJ, Bates ER, Bass TA, Arbor A. Clinical profile of prasugrel, a novel thie-nopyridine. Am Heart J 2008;156:S16-S22.
49. Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: a novel thienopyr-idine anti-platelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007;25:357-374. (Pubitemid 350233359)
50. Crescente M, Jessen G, Momi S, Holtje HD, Gresele P, Cerletti C et al. Interactions of gallic acid, resveratrol, quercetin and aspirin at the platelet cyclooxygenase-1 level. Functional and modelling studies. Thromb Haemost 2009;102:336-346.
51. Pearson DA, Paglieroni TG, Rein D, Wun T, Schramm DD, Wang JF et al. The effects of flavonol-rich cocoa and aspirin on ex vivo platelet function. Thromb Res 2002;106:191-197. (Pubitemid 35248051)
52. Zubair MH, Zubair MH, Zubair MN, Aftab T, Asad F. Augmentation of anti-platelet effects of aspirin. J Pak Med Assoc 2011;61:304-307.
53. Navarro-Nunez L, Lozano ML, Palomo M, Martinez C, Vicente V, Castillo J et al. Api-genin inhibits platelet adhesion and thrombus formation and synergizes with aspirin in the suppression of the arachidonic acid pathway. J Agric Food Chem 2008;56:2970-2976. (Pubitemid 351746016)
54. Prochazkova D, Bousova I, Wilhelmova N. Antioxidant and prooxidant properties of flavonoids. Fitoterapia 2011;82:513-523.
55. Perron NR, Garcia CR, Pinzon JJR, Chaur MN, Brumaghim JL. Antioxidant and prooxidant effects of polyphenol compounds on copper-mediated DNA damage. J Inorg Biochem 2011;105:745-753.
56. Freedman JE, Parker C, Li L, Perlman JA, Frei B, Ivanov V et al. Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release. Circulation 2001;103:2792-2798. (Pubitemid 32550066)
57. Pignatelli P, Ghiselli A, Buchetti B, Carnevale R, Natella F, Germano G et al. Polyphenols synergistically inhibit oxidative stress in subjects given red and white wine. Ather-oscler 2006;188:77-83. (Pubitemid 44142538)
58. Pignatelli P, Pulcinelli FM, Celestini A, Lenti L, Ghiselli A, Gazzaniga PP et al. The fla-vonoids quercetin and catechin synergistically inhibit platelet function by antagonizing the intracellular production of hydrogen peroxide. Am J Clin Nutr 2000;72:1150-1155.
59. 2 receptor. J Thromb Haemost 2005;3:369-376. (Pubitemid 41623628)
60. Jacobson KA, Moro S, Manthey JA, West PL, Ji XD. Interactions of flavones and other phytochemicals with adenosine receptors. Adv Exp Med Biol 2002;505:163-171. (Pubitemid 34526433)
61. Ji XD, Melman N, Jacobson KA. Interactions of flavonoids and other phytochemicals with adenosine receptors. J Med Chem 1996;39:781-788. (Pubitemid 26069697)
62. Gupta K, Panda D. Perturbation of microtubule polymerisation by quercetin through tubulin binding: a novel mechanism of its antiproliferative activity. Biochem 2002;41:13029-13038. (Pubitemid 35215787)
63. Bohl M, Czupalla C, Tokalov SV, Hoflack B, Gutzeit HO. Identification of actin as quercetin-binding protein: an approach to identify target molecules for specific ligands. Anal Biochem 2005;346:295-299. (Pubitemid 41550260)
64. Pawlikowska-Pawlega B, Gruszecki WI, Misiak L, Paduch R, Piersiak T, Zarzyka B et al. Modification of membranes by quercetin, a naturally occurring flavonoid, via its incorporation in the polar head group. Biochim Biophys Acta 2007;1768:2195-2204. (Pubitemid 47379618)
65. Chaudhuri S, Banerjee A, Basu K, Sengupta B, Sengupta PK. Interaction of flavonoids with red blood cell membrane lipids and proteins: antioxidant and antihemolytic effects International. Int J Biol Macromol 2007;41:42-48. (Pubitemid 46476807)
66. Oak MH, Chataigneau M, Keravis T, Chataigneau T, Beretz A, Andriantsitohaina R et al. Red wine polyphenolic compounds inhibit vascular endothelial growth factor expression in vascular smooth muscle cells by preventing the activation of the p38 mitogen-activated protein kinase pathway. Arterioscler Thromb Vasc Biol 2003; 23:1001-1007. (Pubitemid 36713552)
67. Kobuchi H, Roy S, Sen CK, Nguyen HG, Packer L. Quercetin inhibits inducible ICAM-1 expression in human endothelial cells through the JNK pathway. Am J Physiol 1999;277:C403-C411. (Pubitemid 29458175)
68. Lill G, Voit S, Schror K, Weber AA. Complex effects of different green tea catechins on human platelets. FEBS Lett 2003;546:265-270. (Pubitemid 36782423)
69. Maeda-Yamamoto M, Inagaki N, Kitaura J, Chikumoto T, Kawahara H, Kawakami Y et al. O-methylated catechins from tea leaves inhibit multiple protein kinases in mast cells. J Immunol 2004;172:4486-4492. (Pubitemid 38375265)
70. Wright B, Moraes LA, Kemp CF, Mullen W, Crozier A, Lovegrove JA et al. A structural basis for the inhibition of collagen-stimulated platelet function by quercetin and structurally related flavonoids. Br J Pharmacol 2010;159:1312-1325.
71. Hubbard GP, Stevens JM, Cicmil M, Sage T, Jordan PA, Williams CM et al. Quercetin inhibits collagen-stimulated platelet activation through inhibition of multiple components of the glycoprotein VI signalling pathway. J Thromb Haemost 2003;1:1079-1088.
72. Zhang Y, Han G, Fan B, Zhou Y, Zhou X, Wei L et al. Green tea (-)-epigallocatechin-3-gallate down-regulates VASP expression and inhibits breast cancer cell migration and invasion by attenuating Rac1 activity. Eur J Pharmacol 2009;606:172-179.
73. Peluso MR. Flavonoids attenuate cardiovascular disease, inhibit phosphodiesterase, and modulate lipid homeostasis in adipose tissue and liver. Exp Biol Med 2006; 231:1287-1299. (Pubitemid 44330564)
74. Deana R, Turetta L, Donella-Deana A, Donà M, Brunati AM, De Michiel L et al. Green tea epigallocatechin-3-gallate inhibits platelet signalling pathways triggered by both proteolytic and non-proteolytic agonists. Thromb Haemost 2003;89:866-874. (Pubitemid 36603430)
75. Rawel HM, Meidtner K, Kroll J. Binding of selected phenolic compounds to proteins. J Agric Food Chem 2005;53:4228-4235. (Pubitemid 40936789)
76. Wright B, Gibson T, Spencer J, Lovegrove JA, Gibbins JM. Platelet-mediated metabolism of the common dietary flavonoid, quercetin. PLoS One 2010;5:e9673.
77. Gryglewski RJ, Korbut R, Robak J, Swies J. On the mechanism of antithrombotic action of flavonoids. Biochem Pharmacol 1987;36:317-322. (Pubitemid 17003331)
78. Fiorani M, Accorsi A, Cantoni O. Human red blood cells as a natural flavonoid reservoir. Free Rad Res 2003;37:1331-1338. (Pubitemid 37441716)
79. Fiorani M, De Sanctis R, De Bellis R, Dacha M. Intracellular flavonoids as electron donors for extracellular ferricyanide reduction in human erythrocytes. Free Rad Biol Med 2002;32:64-72. (Pubitemid 34045138)
80. Fiorani M, Accorsi A. Dietary flavonoids as intracellular substrates for an erythrocyte trans-plasma membrane oxidoreductase activity. Br J Nutr 2005;94:338-345. (Pubitemid 41404276)
81. Cerecedo D, Stock R, González S, Reyes E, Mondragón R. Modification of actin, myosin and tubulin distribution during cytoplasmic granule movements associated with platelet adhesion. Haematologica 2002;87:1165-1176. (Pubitemid 35397775)
82. Berry S, Dawicki DD, Agarwal KC, Steiner M. The role of microtubules in platelet secretory release. Biochim Biophys Acta 1989;1012:46-56. (Pubitemid 19154918)
83. Pula G, Schuh K, Nakayama K, Nakayama KI, Walter U, Poole AW. PKCdelta regulates collagen-induced platelet aggregation through inhibition of VASP-mediated filo-podia formation. Blood 2006;108:4035-4044. (Pubitemid 44913272)
84. 2+ ions: implications for their antioxidant properties. Biochem J 1998;330:1173-1178.
85. Justino GC, Santos MR, Canario S, Borges C, Florencio MH, Mira L. Plasma quercetin metabolites: structure-antioxidant activity relationships. Arch Biochem Biophys 2004; 432:109-121. (Pubitemid 39425034)
86. Pietta PG. Flavonoids as antioxidants. J Nat Prod 2000;63:1035-1042.
87. Van Acker SABE, Van Den Berg DJ, Tromp MNJL, Griffoen DH, Van Bennekom WP, Van Der Vijgh WJF et al. Structural aspects of antioxidant activity of flavonoids. Free Rad Biol Med 1996;20:275-283.
88. Bors W, Heller W, Michel C, Saran M. Radical chemistry of flavonoid antioxidants. Adv Exp Med Biol 1990;264:165-170. (Pubitemid 20316311)
89. Velioglu YS, Mazza G, Goa L, Oomah BD. Antioxidant activity and total phenolics in selected fruits, vegetables and grain products. J Agric Food Chem 1998;46:4113-4117. (Pubitemid 128488501)
90. Paganga G, Miller N, Rice-Evans CA. The polyphenolic content of fruit and vegetables and their antioxidant activities. What does a serving constitute? Free Rad Res 1999;30:153-162. (Pubitemid 29129466)
91. Rice-Evans C, Miller NJ. Antioxidants-the case for fruits and vegetables in the diet. Br Food J 1995;97:35-40.
92. Kanner J, Franke E, Granit R, German B, Kinsella JE. Natural antioxidants in grapes and wines. J Agric Food Chem 1994;42:64-69.
93. De Whalley CV, Rankin SM, Hoult RS, Jessup W, Leake DS. Flavonoids inhibit the oxidative modification of low density lipoproteins by macrophages. Biochem Pharmacol 1990;39:1743-1750. (Pubitemid 20166625)
94. Cao G, Russell RM, Lischner N, Prior RL. Serum antioxidant capacity is increased by consumption of strawberries, spinach, red wine or vitamin C in elderly women. J Nutr 1998;128:2383-2390. (Pubitemid 29012987)
95. Yamamoto N, Moon JH, Tsushida T, Nagao A, Terao J. Inhibitory effect of quercetin metabolites and their related derivatives on copper ion-induced lipid peroxidation in human low-density lipoprotein. Arch Biochem Biophys 1999;372:347-354. (Pubitemid 30026786)
96. Janisch MK, Williamson G, Needs P, Plumb GW. Properties of quercetin conjugates: modulation of LDL oxidation and binding to human serum albumin. Free Rad Res 2004;38:877-884. (Pubitemid 39077375)
97. Harada M, Kan Y, Naoki H, Fukui Y, Kageyama N, Nakai M et al. Identification of the major antioxidant metabolites in biological fluids of the rat with ingested (+-)-catechin and (2)-epicatechin. Biosci Biotech Biochem 1999;63:973-977. (Pubitemid 129562715)
98. Beretz A, Cazenave JP, Anton R. Inhibition of aggregation and secretion of human platelets by quercetin and other flavonoids: Structure-activity relationships. Agents Actions 1982;12:382-387. (Pubitemid 12026824)
99. Landolfi R, Mower RL, Steiner M. Modification of platelet function and arachidonic acid metabolism by bioflavonoids: Structure-activity relations. Biochem Pharmacol 1984;33:1525-1530. (Pubitemid 14105028)
100. Navarro-Nunez L, Castillo J, Lozano ML, Martinez C, Benavente-Garcia O, Vicente V et al. Thromboxane A2 receptor antagonism by flavonoids: structure-activity relationships. J Agric Food Chem 2009;57:1589-1594.
101. Guerrero JA, Navarro-Nunez L, Lozano ML, Martinez C, Vicente V, Gibbins JM et al. Flavonoids inhibit the platelet TxA(2) signalling pathway and antagonise TxA(2) receptors (TP) in platelets and smooth muscle cells. Br J Clin Pharmacol 2007;64:133-144. (Pubitemid 47063249)
102. Navarro-Nunez L, Rivera J, Guerrero JA, Martinez C, Vicente V, Lozano ML. Differential effects of quercetin apigenin and genistein on signalling pathways of protease-activated receptors PAR(1) and PAR(4) in platelets. Br J Pharmacol 2009; 158:1548-1556.
103. Agullo G, Gamet-Payrastre L, Manenti S, Viala C, Remesy C, Chap H et al. Relationship between flavonoids structure and inhibition of phosphatidylinositol 3-kinase: A comparison with tyrosine kinase and protein kinase C inhibition. Biochem Pharmacol 1997;53:1649-1657. (Pubitemid 27356094)
104. Gamet-Payrastre L, Manenti S, Gratacap MP, Tulliez J, Chap H, Payrastre B. Flavo-noids and the inhibition of PKC and PI 3-kinase. Gen Pharmacol 1999;32:279-286.
105. Holder S, Zemskova M, Zhang C, Tabrizizad M, Bremer R, Neidigh JW et al. Characterisation of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther 2007;6:163-172. (Pubitemid 46206679)
106. Hagiwara M, Inoue S, Tanaka T, Nunoki K, Ito M, Hidaka H. Differential effects of flavonoids as inhibitors of tyrosine protein kinases and serine/threonine protein kinases. Biochem Pharmacol 1988;37:2987-2992.
107. Cochet C, Feige JJ, Pirollet F, Keramidas M, Chambaz EM. Selective inhibition of a cyclic nucleotide independent protein kinase (G-type casein kinase) by quercetin and related polyphenols. Biochem Pharmacol 1982;31:157-1361.
108. Zheng J, Ramirez VD. Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. Br J Pharmacol 2000;130:1115-1123. (Pubitemid 30453547)
109. Dufour C, Dangles O. Flavonoid-serum albumin complexation: determination of binding constants and binding sites by fluorescence spectroscopy. Biochim Biophys Acta 2005;1721:164-173. (Pubitemid 40093524)
110. Sicheri F, Moarefi I, Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature 1997;385:602-609. (Pubitemid 27087567)
111. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin and staurosporine. Mol Cell 2000;6:909-919.
112. Plaper A, Golob M, Hafner I, Oblak M, Solmajer T, Jeralab R. Characterization of quercetin binding site on DNA gyrase. Biochem Biophys Res Commun 2003;306:530-536. (Pubitemid 36683107)
113. Gradisar H, Pristovsek P, Plaper A, Jerala R. Green tea catechins inhibit bacterial DNA gyrase by interaction with its ATP binding site. J Med Chem 2007;50:264-271. (Pubitemid 46147707)
114. Goodford PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 1985;28:849-857. (Pubitemid 15012490)
115. Zhang XH, Zou ZQ, Xu CW, Shen YZ, Li D. Myricetin induces G2/M phase arrest in HepG2 cells by inhibiting the activity of the cyclin B/Cdc2 complex. Mol Med Report 2011;4:273-272.
116. Jung SK, Lee KW, Kim HY, Oh MH, Byun S, Lim SH et al. Myricetin suppresses UVB-induced wrinkle formation and MMP-9 expression by inhibiting Raf. Biochem Pharmacol 2010;79:1455-1461.
117. Li L, Wei DQ, Wang JF, Chou KC. Computational studies of the binding mechanism of calmodulin with chrysin. Biochem Biophys Res Commun 2007;358:1102-1107. (Pubitemid 46829002)
118. Cuccioloni M, Mozzicafreddo M, Bonfili L, Cecarini V, Eleuteri AM, Angeletti M. Natural occurring polyphenols as template for drug design. Focus on serine proteases. Chem Biol Drug Des 2009;74:1-15.
119. Matter WF, Brown RF, Vlahos CJ. The inhibition of phosphatidylinositol 3-kinase by quercetin and analogs. Biochem Biophys Res Comm 1992;186:624-631.
120. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994;269:5241-5248.
121. Huang H, Jia Q, Ma J, Qin G, Chen Y, Xi Y et al. Discovering novel quercetin-3-O-amino acid-esters as a new class of Src tyrosine kinase inhibitors. Eur J Med Chem 2009;44:1982-1989.
122. Thanigaimalai P, Le Hoang TA, Lee KC, Sharma VK, Bang SC, Yun JH et al. Synthesis and evaluation of novel chromone analogs for their inhibitory activity against interleukin-5. Eur J Med Chem 2010;45:2531-2536.
123. Jung SH, Cho SH, Dang TH, Lee JH, Ju JH, Kim MK et al. Structural requirement of isoflavonones for the inhibitory activity of interleukin-5. Eur J Med Chem 2003;38:537-545.
124. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95-105.
125. Bain J, McLauchlan H, Elliott M, Cohen P. The selectivity of protein kinase inhibitors: an update. Biochem J 2003;371:199-204. (Pubitemid 36458094)
126. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007;408:297-315.